general
- Generic Name : Ziv-Aflibercept
- Trade Names/Brand Names of Ziv-Aflibercept(International) : Zaltrap
prescription
This medication, a recombinant fusion protein, is prescribed alongside other medications for metastatic colorectal cancer (mCRC). It functions by inhibiting specific growth factors responsible for the formation of new blood vessels in tumors, thereby impeding tumor growth.
risk factors
N/A
side effects
- Infections: Such as urinary tract infection
- Blood: Manifesting as a decrease in white blood cells and platelets
- Metabolic: Notably, decreased appetite and dehydration
- Central Nervous System: May include headaches
- Heart: Possibly resulting in high blood pressure
- Respiratory: Symptoms like nosebleeds, difficulty breathing, throat pain, and a runny nose
- Gastrointestinal: Potential side effects encompass diarrhea, mouth ulcers, abdominal pain, piles, rectal bleeding, and anal coldness
- Skin: Including conditions like Palmar-Plantar Erythrodysesthesia Syndrome and hyperpigmentation
- Genitourinary: May involve the presence of protein in the urine
- General: Manifestations such as fatigue, weakness, and weight loss
dosage
The recommended dosage entails an infusion of 4 mg/kg administered over a one-hour period, repeated every two weeks.
how to take
It is provided as a solution for injection, meant to be administered by a healthcare provider into the vein.
warning
- If a fistula develops, discontinue this medication
- Regularly monitor blood pressure during treatment with this medication
- Patients may face an elevated risk of arterial thromboembolic events, gastrointestinal perforation, and RPLS (posterior reversible encephalopathy syndrome). If any of these conditions arise, promptly consult your healthcare provider
storage
Follow the storage instructions provided by your physician for this medication